Strategic Acquisition Interest Halda’s high-profile M&A activity signals strong buyer appetite from major pharma and potential interest from Johnson & Johnson, presenting opportunities to engage on licensing, collaboration, or co-development deals around RIPTAC platforms and adjacent modalities.

Proximity & Collaboration Recent partnership with Proximabio and proximity-based modality expansion creates a pathway for strategic alliances, enabling joint programs, shareable IP, and accelerated progression of RIPTAC and related technologies with tier-one partners.

Clinical Leadership Appointment of a new Chief Medical Officer and ongoing clinical development in prostate cancer with expansion to major solid tumors suggests readiness for late-stage partnerships, sponsored trials, and co-development discussions with pharma with oncology franchises.

Pipeline Value A growing RIPTAC pipeline across solid tumors positions Halda as a versatile partner for oncology programs, offering potential licensing opportunities or milestone-driven collaborations to advance multiple drug candidates concurrently.

Geographic & Facility Strength New Haven headquarters with state-of-the-art labs in Science Park and a focused biotech ecosystem signals reliability for partner visits, on-site collaborations, and regional manufacturing or translational support engagements.